Stocks and Investing Stocks and Investing
Thu, July 6, 2023
Wed, July 5, 2023
Mon, July 3, 2023
Fri, June 30, 2023

David Lebowitz Maintained (BMRN) at Hold with Decreased Target to $96 on, Jun 30th, 2023


Published on 2024-10-28 04:35:59 - WOPRAI, David Lebowitz
  Print publication without navigation


David Lebowitz of Citigroup, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Hold with Decreased Target from $103 to $96 on, Jun 30th, 2023.

David has made no other calls on BMRN in the last 4 months.



There are 9 other peers that have a rating on BMRN. Out of the 9 peers that are also analyzing BMRN, 3 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Luca Issi of "RBC Capital" Reiterated at Hold and Held Target at $100 on, Thursday, April 27th, 2023
  • Kostas Biliouris of "BMO Capital" Maintained at Hold with Decreased Target to $102 on, Tuesday, March 7th, 2023
  • Whitney Ijem of "Canaccord Genuity" Maintained at Hold with Decreased Target to $112 on, Tuesday, February 28th, 2023


These are the ratings of the 6 analyists that currently disagree with David


  • Tiago Fauth of "Credit Suisse" Initiated at Buy and Held Target at $120 on, Wednesday, June 14th, 2023
  • Christopher Raymond of "Piper Sandler" Maintained at Buy with Decreased Target to $125 on, Thursday, April 27th, 2023
  • Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Decreased Target to $120 on, Thursday, April 27th, 2023
  • William Pickering of "Bernstein" Initiated at Sell and Held Target at $81 on, Tuesday, March 21st, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $131 on, Tuesday, February 28th, 2023
  • Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $118 on, Tuesday, February 28th, 2023